Design: A six-centre study in Japan during the winter of 1999-2000 assessed the in vitro activity of >20 antimicrobial agents against the common respiratory pathogens Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. The minimum inhibitory concentrations (MIC) of each antimicrobial was determined against these isolates using National Committee for Clinical Laboratory Standards (NCCLS) methodology. Results: Among S. pneumoniae isolates, 44.5% were penicillin resistant. The macrolide resistance rate was 77.9% with 90.5% of penicillin-resistant strains also being macrolide resistant. Resistance mechanisms in macrolide-resistant isolates were identified as mef(A) or erm(B) in 42.5% and 52.5%, respectively. Of the fluoroquinolone-resistant isolates (1.3%), most were also penicillin and macrolide resistant. All strains were inhibited by telithromycin at 1 mg/L. Among S. pyogenes isolates, erythromycin resistance was 17.5% overall but showed considerable variation among the six centres. For H. influenzae, 8.5% produced b-lactamase and a single blactamase-negative, ampicillin-resistant isolate (0.36%) was obtained, and there was no fluoroquinolone resistance. All isolates were susceptible to telithromycin.
Introduction
The prevalence of resistant isolates of common bacterial respiratory tract pathogens is increasing, and nowhere more so than in Asia. In some Asian countries, penicillin resistance may be as high as 70%. [1] [2] [3] In the last decade, macrolide resistance has also increased dramatically, exceeding penicillin resistance in some areas, 2 and growing resistance to chloramphenicol, co-trimoxazole and tetracycline continues relentlessly. 4 Most respiratory tract infections are viral in origin but are frequently followed by secondary infections resulting from opportunistic invasion by commensal respiratory bacteria. The four most important bacterial pathogens associated with communityacquired upper and lower respiratory tract infections (RTIs -acute/chronic sinusitis, acute/chronic otitis media, acute/chronic pharyngitis, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and acute bacterial exacerbation of chronic obstructive airways disease) are Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. Less commonly, atypical and intracellular pathogens including Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila (Chlamydia) pneumoniae are also found as causes of community-acquired RTIs. [5] [6] [7] S. pneumoniae in particular has acquired resistance to several classes of antimicrobial compounds, including penicillins, macrolides and fluoroquinolones, by a variety of mechanisms. 8 For Haemophilus species and M. catarrhalis, b-lactamase production is the principal mechanism of resistance to penicillins and cephalosporins. The choice of antimicrobial therapy in communityacquired RTIs is generally empirical and complicated by increasing bacterial resistance. Effective strategies for ensuring adequate antimicrobial therapy are therefore necessary but may only be achieved through an understanding of the geographic variation in resistance and by monitoring trends in resistance development.
Established in 1999, PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is an international surveillance study to chart the prevalence of important resistance phenotypes and examine the susceptibility of community-acquired RTI pathogens to a range of antimicrobial compounds. Telithromycin is the first ketolide antibacterial to be approved for clinical use for the treatment of upper and lower RTIs. With over 35 countries and 500 centres now participating, PROTEKT is able to concentrate on defining trends in specific regions and countries. Detailed data from the examination of isolates of S. pneumoniae, H. influenzae, M. catarrhalis and S. pyogenes collected during the 1999-2000 winter season in Japan are now presented and, where possible, related to trends seen in previous studies. 2, 9, 10 Materials and methods
Participating centres
During the 1999-2000 winter season, six centres took part in the study: Kanagawa, Sendai, Tokyo (two centres), Nagasaki and Osaka.
Bacterial isolates
Centres were asked to collect the following isolates from patients with community-acquired upper and lower RTIs: 40 isolates each of S. pneumoniae and H. influenzae, 25 of S. pyogenes, and 20 of M. catarrhalis. Sources for isolates were cultures from blood, sputum, bronchoalveolar lavage, middle ear fluid, nasopharyngeal swab or aspirate, and sinus aspirate. Duplicate strains or strains originating from previous collections were not accepted.
Identification and antimicrobial susceptibility testing
Isolates were identified at source and re-identified at the central laboratory by methods previously described in detail. 11 Minimum inhibitory concentrations (MICs) were determined using previously described broth microdilution methods, 11 
Macrolide resistance mechanism detection
For S. pneumoniae, the presence of resistance mechanisms for both MLS B (erm) and M-resistance (mef) was analysed using a rapid-cycle multiplex PCR method with probe detection. This method detects erm(A), erm(A) subclass erm(TR), erm(B), erm(C), and mef(A) genes. 13 
Results

Streptococcus pneumoniae
A total of 308 S. pneumoniae isolates from the six participating centres were tested. The prevalence of penicillin resistance (MIC 2 mg/L) was 44.5% overall and ranged narrowly between 44.2% and 48.4% for five of the six centres, with Osaka lower at 36.4%. Penicillin-intermediate (MIC 0.12-1 mg/ L) isolates (19.8% overall) were less evenly distributed, with centres reporting between 7.7% (Kanagawa) and 31.6% (Sendai) ( Table 1 ). The prevalence of macrolide resistance (erythromycin MIC 1 mg/ L) was 77.9%, far exceeding that of penicillin resistance, and ranged from 67.3% (Kanagawa) to 86.4% (Osaka) ( Table 1 ). Only one strain was of the intermediate type (erythromycin MIC 0.5 mg/L). Almost half of all S. pneumoniae isolates (40.3%) were coresistant to penicillin and erythromycin (macrolide) ( Table 1) .
Of the 239 macrolide-resistant isolates of S. pneumoniae analysed for their resistance mechanism, 52.7% carried erm(B) (MLS B resistance) and 42.7% carried mef(A) (efflux resistance), with 3.3% (n = 8) of isolates carrying both mechanisms (mef(A)+erm(B)) ( Table 2) . ermB isolates were evenly distributed across the three penicillin resistance phenotypes, whereas mef(A) resistance was associated predominantly with penicillin-resistant (70.6%) rather than penicillin-susceptible (16.7%) isolates.
Among the b-lactams, the most active were cefditoren (MIC 90 1 mg/L, 98.4% of all isolates susceptible) and amoxicillin-clavulanate (MIC 90 2 mg/L, 96.4% of all isolates susceptible). Both retained >90% activity among the penicillin-and macro- lide-resistant isolates ( Table 3 ). With the exception of telithromycin and the fluoroquinolones, susceptibility to non-b-lactams was low ( Table 3 ). Among the penicillin-resistant isolates, <10% were susceptible to macrolides and tetracycline.
Erythromycin, roxithromycin, azithromycin and clarithromycin gave typical trimodal MIC distributions with clusters of isolates inhibited by 0.06-0.12 mg/L, 2-4 mg/L and >32->64 mg/L ( Figure 1 ). Small numbers of isolates were inhibited by each inter-mode concentration of each antimicrobial. Rokitamycin and clindamycin showed two obvious clusters in their MIC distributions, with just under half the isolates inhibited within the lowest concentration cluster. This was reflected in the MIC 50 (0.12 mg/L) for rokitamycin and clindamycin, which differed considerably from the four macrolides with typical trimodal MIC distributions (MIC 50 4-8 mg/L). Telithromycin showed much lower mode MIC (0.06 mg/L) and MIC 90 (0.25 mg/L) than the macrolides (Figure 1 ). Among the macrolide-resistant isolates, the telithromycin MIC 90 value was markedly higher for the erm(B) genotype (0.5 mg/L) than the mef(A) genotype (0.12 mg/L). Despite a shift upwards in the distribution of telithromycin MIC values among the macrolide-resistant isolates (particularly among the eight erm(B)+mef(A) strains (Figure 2) ) compared with macrolide-susceptible isolates (telithromycin MIC 90 0.015 mg/L), all isolates were susceptible to telithromycin at 1 mg/L. Fluoroquinolone resistance (levofloxacin MIC 8 mg/L) was 1.3% overall, with little variation among centres. Of the four fluoroquinolone-resistant isolates, three were penicillin-resistant and one was penicillin-susceptible. All four fluoroquinolone-resistant isolates were also macrolide-and tetracycline-resistant. Susceptibility to telithromycin was unaffected by fluoroquinolone resistance. Overall, of those antibacterial agents tested, the most active against S. pneumoniae in the winter season 1999-2000 in Japan (in terms of potency and susceptibility percentage) were telithromycin, sparfloxacin, levofloxacin, cefditoren and amoxicillin-clavulanate.
Streptococcus pyogenes
The most potent antimicrobial against S. pyogenes isolates was penicillin (MIC 90 0.008 mg/L) against which all 120 isolates were susceptible. Macrolide resistance showed considerable variation among the six centres, with the highest prevalence (42.1%) in Sendai and 0% in Nagasaki (although this centre collected only three isolates). Overall, 82.5% of isolates were erythromycin-susceptible. Among the 21 (17.5%) erythromycin-resistant isolates, the mechanisms of resistance detected were mef(A) in 15 isolates, erm(A) subclass erm(TR) in five isolates and erm(B) in one isolate. Telithromycin had mode MIC (0.015 mg/L) and MIC 90 (0.25 mg/L), values which were 16-to 32-fold lower than those of the tested macrolides.
Haemophilus influenzae
b-lactamase production amongst H. influenzae isolates (n = 281) had an overall incidence of 8.5% and variation among centres of 5.1% to 11.5%. A single b-lactamase-negative, ampicillin-resistant (MIC 4 mg/L) strain (BLNAR) was identified (from Sendai). A further nine b-lactamase-negative isolates, however, had ampicillin MICs of 2 mg/L (intermediate resistance according to NCCLS breakpoints). Comparative in vitro activity of all antimicrobial compounds tested against H. influenzae and categorised by b-lactamase production is shown in Table  4 . Of the b-lactams tested, cefditoren (MIC 90 0.06 mg/L; no NCCLS breakpoint) and cefixime (MIC 90 0.25 mg/L; 100%) were the most active.
Chloramphenicol resistance had low prevalence (3.6%), with nine of the ten nonsusceptible isolates also b-lactamase-positive. Similarly, tetracycline resistance was low (6.4%) with resistant isolates predominantly b-lactamase-positive (12/18). The MIC 90 values for both chloramphenicol and tetracycline among b-lactamase-positive H. influenzae isolates (16 mg/L) were 16 times greater than for blactamase-negative isolates ( Table 4 ).
The MICs of the macrolides and telithromycin to H. influenzae isolates followed unimodal distributions in the rank order: azithromycin (MIC 90 1 mg/L) > telithromycin (MIC 90 2 mg/L) > rokitamycin (MIC 90 8 mg/L) > clarithromycin and roxithromycin (MIC 90 16 mg/L), (Table 4 ). There was no correlation between ketolide/macrolide susceptibility and b-lactamase production.
Moraxella catarrhalis
Of the 122 M. catarrhalis isolates, 118 (96.7%) were b-lactamase-positive. With the exception of some b-lactams (ampicillin, cefaclor, cefuroxime and cefcapene), all antimicrobials tested showed good activity (MIC 90 values of 1 mg/L) against M. catarrhalis isolates (Table 4 ). Cefixime was the most active b-lactam (MIC 90 0.25 mg/L), followed by cefdinir and cefditoren (both, MIC 90 0.5 mg/L) ( Table 4 ). The rank order of activity of the MLS class of antimicrobials was azithromycin (MIC 90 0.06 mg/ L) > telithromycin, clarithromycin, and rokitamycin (MIC 90 0.25 mg/L) > roxithromycin (MIC 90 0.5 mg/ L). Sparfloxacin and tosufloxacin were the most potent (MIC 90 0.008 mg/L) fluoroquinolones.
Discussion
Streptococcus pneumoniae
Previous reports have demonstrated the increasing prevalence of penicillin resistance of both intermediate (MIC 0.12-1 mg/L) and resistant (MIC
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M. Inoue et al. 2 mg/L) phenotypes amongst isolates of S. pneumoniae. 2, 9, 14 During the 1999-2000 winter season, 44.5% of S. pneumoniae RTI isolates from Japan were penicillin resistant and 19.8% were penicillin intermediate, a pattern with small geographic variation throughout Japan (Table 1 ). In previous studies, Yoshida et al. 15 found that penicillin resistance increased from 4.3% in 1988 to 9.8% in 1992 and Sahm et al. 10 reported 10.1% penicillin resistance for the 1997-98 winter season. Therefore, penicillin resistance in Japan is increasing and current data strongly suggest that the trend has accelerated in recent years. Resistance to penicillin in S. pneumoniae is mediated by changes in the affinity of high molecular weight penicillin binding proteins (PBPs) for their substrates. As these PBPs are also targets for other b-lactams, the activity of aminopenicillins, cephalosporins and carbapenems is also reduced against penicillin-resistant strains. This is most evident with compounds considered active only against penicillin-susceptible S. pneumoniae, such as cefa-clor and cefixime. Cefuroxime, cefpodoxime and cefdinir retained some activity against penicillinintermediate isolates (approximately 40%), but little or no activity against resistant isolates. This perhaps reflects the trend towards greater resistance as previous work has shown that cefuroxime, among other cephalosporins, can retain activity against many penicillin-resistant strains. 16, 17 The most effective b-lactams for the 1999-2000 winter season in Japan were cefditoren and amoxicillinclavulanate, with over 90% susceptibility among penicillin-resistant strains. The amoxicillin-clavulanate results can be extrapolated to include amoxicillin as an effective b-lactam (92% susceptibility among penicillin-resistant strains), although amoxicillin itself was not tested against S. pneumoniae.
Macrolides form the principal alternative to blactams for the treatment of lower RTIs involving S. pneumoniae. However, it is now clear that this class of compounds, including erythromycin, clarithromycin and azithromycin, is seriously compromised by the development of resistance not only as a result of Antimicrobial susceptibility of respiratory tract pathogens 33 the increasing prevalence of penicillin-resistant pneumococci but also, in Japan, among penicillinsusceptible strains. Typical of the Far East, S. pneumoniae macrolide resistance in Japan is high (77.9%) with some centre variation (67.3-86.4%). This finding of 77.9% is considerably higher than the 66.5% reported for the 1997-1998 winter season. 10 The proportion of penicillin-resistant isolates (n = 137) that are also macrolide-resistant has not increased over the same period (124/137, 90.5%) and is slightly lower than the previous study (1997) (1998) 95 .5%).
Two main mechanisms are known to account for macrolide resistance in S. pneumoniae. With the first, resistance is associated with specific mutation within the erm gene that confers resistance to most macrolides, lincosamides and streptogramin B antibiotics. 18 With the second, the so-called M phenotype, resistance is mediated by an efflux mechanism due to the presence of the mef(A) gene that confers resistance to 14-and 15-membered macrolides. 19 Growing macrolide resistance is of increasing concern, especially that dependent upon the erm(B) genotype; not only because it is the more potent macrolide resistance, but because resistance to other antimicrobial compounds appear preferentially to be associated with it. This study shows that in Japan, the distribution of erm(B) and mef(A) are similar.
Telithromycin, a synthetic ketolide derived by chemical modification of desclarithromycin, was designed to maintain potent antimicrobial activity against community-acquired respiratory tract infection (CARTI) pathogens, even macrolide-resistant pneumococci, and not to induce resistance due to erm(B). 20 There was, however, an upward shift in telithromycin MICs among the isolates with erm(B)mediated macrolide resistance compared with mef(A) strains. This effect of erm(B) resistance on the activity of telithromycin has been reported previously although, as in this study, all the isolates were still found to be inhibited by telithromycin at 1 mg/L. Worldwide incidence of fluoroquinolone-resistant S. pneumoniae (levofloxacin MIC 8 mg/L) is rare, although it tends to be concentrated in pockets of Asia (specifically Hong Kong) and North America. The four (1.3%) resistant isolates from Japan were obtained from four different centres, and would therefore suggest random distribution and independent origin.
The b-lactamases of M. catarrhalis are inhibited by clavulanic acid and the combination of amoxicillin-clavulanic acid has been shown to be highly active against this species. [25] [26] [27] [28] [29] Indeed, in this study, among b-lactamase-positive M. catarrhalis the MIC 90 for unprotected ampicillin was high at 16 mg/L, in contrast with 0.25 mg/L for amoxicillin-clavulanate.
Summary
Despite growing public awareness Japan has witnessed increased and even accelerating resistance to the macrolides and to b-lactams. Fluoroquinolone resistance, albeit at a low level, would also appear to be endemic. This study documents the high prevalence of antimicrobial resistance and co-resistance among respiratory pathogens in Japan.
For a great proportion of respiratory infections that require antimicrobial therapy, amoxicillin remains largely effective; however, in Japan, the preference is for the use of newer drugs as firstline treatment. This study reinforces the necessity for judicious use of old and new antimicrobial compounds and, with the technical ability that is now available, to evaluate resistance at a genetic level to monitor more detailed patterns of emergence.
